The number of total prevalent cases of diabetic nephropathy in the diagnosed diabetic population across the seven major markets (7MM) — the US, France, Germany, Italy, Spain, UK and Japan — is expected to increase from approximately 14 million in 2012 to 19.87 million by 2022, at an Annual Growth Rate (AGR) of 4.16%, forecasts research and consulting firm reportstack and globaldata.
The company’s latest report EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022 states that out of the 7MM, the US and Japan had the largest amounts of diagnosed diabetic nephropathy prevalent cases in 2012, with 6.1 million and 3.29 million cases, respectively. This trend will continue up to 2022, when the US will lead the 7MM with a population of 9.67 million people affected by the condition, followed by Japan, with 3.9 million.
Aneesh George, GlobalData’s Senior Epidemiologist, says: “With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease. The condition also accounts for nearly 40% of end-stage renal disease (ESRD) cases in the US and Europe, which requires dialysis or kidney transplantation.”
Furthermore, such prevalence can be a major monetary burden upon individuals and healthcare systems across the globe, says George.
“Controlling blood glucose levels in the diabetic population is essential to reducing the occurrence of diabetic nephropathy and its subsequent progression to ESRD. This will, in turn, alleviate the immense economic cost associated with the management of diabetic nephropathy and ESRD,” the analyst concludes.
No comments:
Post a Comment